|
Cooperative Study of Factor VIII Inhibitors Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Cooperative Study of Factor VIII Inhibitors conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Cooperative Study of Factor VIII Inhibitors Clinical research trials and Cooperative Study of Factor VIII Inhibitors health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Cooperative Study of Factor VIII Inhibitors. Cooperative Study of Factor VIII Inhibitors Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Cooperative Study of Factor VIII Inhibitors clinical trial. Subjects frequently get the best healthcare possible for their Cooperative Study of Factor VIII Inhibitors condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cooperative Study of Factor VIII Inhibitors  Cooperative Study of Factor VIII Inhibitors
Cooperative Study of Factor VIII Inhibitors
For Condition: Blood Coagulation Disorders,Hematologic Diseases,Hemophilia A,Hemorrhagic Disorders
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To test the efficacy of prothrombin complex concentrates (Factor IX) in the treatment of hemophiliac patients who had inhibitors to Factor VIII.
Details: BACKGROUND: Despite major advances in the treatment of patients with hemophilia, a serious remaining challenge was presented by the occurrence of circulating inhibitors to Factor VIII. Because of lack of information on the natural course of patients with Factor VIII inhibitors, the relative efficacy of various modes of therapy was not established. The Division of Blood Diseases and Resources decided to sponsor a clinical investigation which would evaluate populations of hemophilia patients for Factor VIII inhibitors, follow up these patients to provide information on the natural history of the inhibitor in the hemophilia patients, and make available a reference center to monitor results and attain uniformity. Treatment of a patient with a severe inhibitor and consequent bleeding remained a problem. Management included protracted treatment with Factor VIII, use of immunosuppressive agents and prothrombin complex (or Factor IX) concentrates. The rationale for Factor IX was that it bypassed the defect in Factor VIII caused by the inhibitor. This method of therapy attracted wide popularity, but the success was greatly debated. It was intended at the very outset of the Factor VIII study that therapeutic trials involving patients with inhibitors would not be a prime function, but that such studies would be monitored if necessary. A controlled trial of Factor IX concentrates therapy was strongly advised by the DBDR Advisory Committee. Accordingly, during fiscal year 1978, a protocol for a double-blind control study was developed by the Factor VIII inhibitor group. The trial began in the spring of 1978, and the intervention terminated about one year later. DESIGN NARRATIVE: Double-blind study; patients served as their own controls. A total of 51 patients each received a single large dose of Konyne, Proplex, or diluted albumin (as a control). Joint bleeding of the elbow, knee, and ankle was evaluated six hours after each dose.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Male
Protocol Entry Criteria: Males with hemophilia, not stratified as to ethnic group.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LouisAledort, , Mount Sinai Medical Center
Additional Information:
Study ID Numbers: 302;
Study Start Date: July 1978
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000582
Other Hemophilia A Studies:
1. Cooperative Study of Factor VIII Inhibitors
Related Studies:
Other Hemophilia A Clinical Trials
Other Clinical Trials
Other Clinical Trials
Cooperative Study of Factor VIII Inhibitors
|
|
|
|
|
|
|
|
